Intensity Therapeutics Provides Update on Progress of Ph 3 Sarcoma Program
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Intensity Therapeutics Presents Positive INT230-6 Data at the 2023 SABCS
Intensity Selected for Spotlight Oral Presentation at the 2023Cancer Symposium
WESTPORT, Conn., Nov. 2, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that safety, tolerability and efficacy data from IT-01, the company's ongoing Phase 1/2 clinical trial of INT230-6, either as a monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, was presented at the Connective Tissue Oncology Society 2023 Annual Meeting being held in Dublin, Ireland from November 1-4, 2023. The poster will be displayed for the duration of the Annual Meeting.
WESTPORT, Conn., Aug. 14, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Cancer biotech Intensity Therapeutics launched an IPO as it aims to advance a therapy being tested in sarcoma and breast cancer.